Elinzanetant reduced the frequency and severity of menopause-associated vasomotor symptoms in two phase 3 clinical trials. Elinzanetant was safe and ...
1. This prospective study found that women with severe premenstrual disorders (PMDs) were at increased risk for early onset of ...
1. Fezolinetant 30 mg and 45 mg significantly reduced the frequency and severity of vasomotor symptoms compared to placebo. 2. ...
1. Paroxetine use was associated with decreased frequency of hot flashes and lower composite vasomotor symptom (VMS) severity score. 2. ...
